Priority Medicines for Europe and the World

[1]  Carl T. Bergstrom,et al.  The epidemiology of antibiotic resistance in hospitals: paradoxes and prescriptions. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[2]  K. Ko,et al.  High Prevalence of Antimicrobial Resistance among Clinical Streptococcus pneumoniae Isolates in Asia (an ANSORP Study) , 2004, Antimicrobial Agents and Chemotherapy.

[3]  H. Mobley,et al.  Development of an Intranasal Vaccine To Prevent Urinary Tract Infection by Proteus mirabilis , 2004, Infection and Immunity.

[4]  A. Voss,et al.  Controlling glycopeptide-resistant enterococci. , 1997, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[5]  V. Fischetti,et al.  Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[6]  B. Chabner,et al.  Beyond fast track for drug approvals. , 2004, The New England journal of medicine.

[7]  K. Ekdahl,et al.  Previous Antibiotic Consumption and Other Risk Factors for Carriage of Penicillin-Resistant Streptococcus pneumoniae in Children , 1998, European Journal of Clinical Microbiology and Infectious Diseases.

[8]  D. Shlaes,et al.  The United States Food and Drug Administration and the end of antibiotics. , 1935, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  M. Larkin.  Daptomycin approved for skin and skin-structure infections , 2003 .

[10]  I. Okeke,et al.  Socioeconomic and behavioral factors leading to acquired bacterial resistance to antibiotics in developing countries. , 1999, Emerging infectious diseases.

[11]  M. Kelsey,et al.  The Second National Prevalence Survey of infection in hospitals--overview of the results. , 1996, The Journal of hospital infection.

[12]  G Sherman,et al.  Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. , 1999, Chest.

[13]  D. Haldane,et al.  Comparison of the Velogene Rapid MRSA Identification Assay, Denka MRSA-Screen Assay, and BBL Crystal MRSA ID System for rapid identification of methicillin-resistant Staphylococcus aureus. , 2001, Diagnostic microbiology and infectious disease.

[14]  F. M. Stewart,et al.  The population genetics of antibiotic resistance. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  J. Verhoef,et al.  Frequency of Isolation and Antimicrobial Resistance of Gram-Negative and Gram-Positive Bacteria from Patients in Intensive Care Units of 25 European University Hospitals Participating in the European Arm of the SENTRY Antimicrobial Surveillance Program 1997–1998 , 2001, European Journal of Clinical Microbiology and Infectious Diseases.

[16]  S. Black,et al.  Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. , 2002, The New England journal of medicine.

[17]  T. Ida,et al.  CP6679, a new injectable cephalosporin with broad spectrum and potent activities against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa , 2002, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[18]  D. Andersson,et al.  Persistence of antibiotic resistant bacteria. , 2003, Current opinion in microbiology.

[19]  G. Leverson,et al.  Phase 2 clinical trial of a vaginal mucosal vaccine for urinary tract infections. , 2003, The Journal of urology.

[20]  K. Bush,et al.  Novel antibacterial agents for the treatment of serious Gram-positive infections. , 2003, Expert opinion on investigational drugs.

[21]  F. Rodríguez Sánchez,et al.  [Rational use of antibiotics in pediatrics: impact of a rapid test for detection of beta-haemolytic group A streptococci in acute pharyngotonsillitis]. , 2000, Anales espanoles de pediatria.

[22]  M. Enright,et al.  Vancomycin Susceptibility within Methicillin-resistant Staphylococcus aureus Lineages , 2004, Emerging infectious diseases.

[23]  S. Projan,et al.  Why is big Pharma getting out of antibacterial drug discovery? , 2003, Current opinion in microbiology.

[24]  Mitchell L. Cohen.  Epidemiology of Drug Resistance: Implications for a Post—Antimicrobial Era , 1992, Science.

[25]  F. Vandenesch,et al.  Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  I. Phillips,et al.  Antibiotic clinical trials—the Witley Park Symposium , 1999 .

[27]  Rino Rappuoli,et al.  Reverse Vaccinology and Genomics , 2003, Science.

[28]  D. Shlaes.  The abandonment of antibacterials: why and wherefore? , 2003, Current opinion in pharmacology (Print).

[29]  R. Spencer,et al.  Surveillance of antibiotic resistance in European ICUs. , 2001, The Journal of hospital infection.

[30]  Thomas D Gootz.  The current state of antibacterial research , 2003, Expert review of anti-infective therapy.

[31]  D. Calfee,et al.  Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  F. Baquero,et al.  Strategies to minimize the development of antibiotic resistance. , 1997, Journal of chemotherapy.

[33]  Clement S. Chu,et al.  A New Class of Bacterial RNA Polymerase Inhibitor Affects Nucleotide Addition , 2003, Science.

[34]  H. Endtz,et al.  Quinolone resistance in campylobacter isolated from man and poultry following the introduction of fluoroquinolones in veterinary medicine. , 1991, The Journal of antimicrobial chemotherapy.

[35]  M. Chapman,et al.  Antibody responses and protection from pyelonephritis following vaccination with purified Escherichia coli PapDG protein. , 2004, The Journal of urology.

[36]  R. Jones,et al.  Oxazolidinones: a review. , 2000, Drugs.

[37]  R. Marples,et al.  A major outbreak of methicillin-resistant Staphylococcus aureus caused by a new phage-type (EMRSA-16) , 1995, The Journal of hospital infection.

[38]  J. Turnidge.  Impact of Antibiotic Resistance on the Treatment of Sepsis , 2003, Scandinavian journal of infectious diseases.

[39]  H. Neu,et al.  The Crisis in Antibiotic Resistance , 1992, Science.

[40]  J. Powers,et al.  Trends in antimicrobial drug development: implications for the future. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[41]  C. Merril,et al.  The prospect for bacteriophage therapy in Western medicine , 2003, Nature Reviews Drug Discovery.

[42]  J. Hendley.  Clinical practice. Otitis media. , 2002, The New England journal of medicine.

[43]  T. Shakya.,et al.  Historical Introduction , 2002, Jewish Identities: Fifty Intellectuals Answer Ben-Gurion.

[44]  Stephan Harbarth,et al.  Antibiotic Selection Pressure and Resistance in Streptococcus pneumoniae and Streptococcus pyogenes , 2004, Emerging infectious diseases.

[45]  B. Levin,et al.  The biological cost of antibiotic resistance. , 1999, Current opinion in microbiology.

[46]  K. Towner,et al.  Detection of Methicillin-Resistant Staphylococcus aureus (MRSA) in Blood with the EVIGENE MRSA Detection Kit , 2003, Journal of Clinical Microbiology.

[47]  C. Whitney,et al.  Vaccines as tools against resistance: the example of pneumococcal conjugate vaccine. , 2004, Seminars in pediatric infectious diseases.

[48]  J. Coast,et al.  Over-the-counter antimicrobials: the hidden costs of resistance. , 1996, The Journal of antimicrobial chemotherapy.

[49]  O. Cars,et al.  Moving from recommendation to implementation and audit: part 1. Current recommendations and programs: a critical commentary. , 2002, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[50]  O. Cars,et al.  Moving from recommendation to implementation and audit: part 2. Review of interventions and audit. , 2002, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[51]  R. Anderson,et al.  Studies of antibiotic resistance within the patient, hospitals and the community using simple mathematical models. , 1999, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[52]  J. Powers.  Development of drugs for antimicrobial-resistant pathogens , 2003, Current opinion in infectious diseases.

[53]  P. Youngman,et al.  Antimicrobials: new solutions badly needed. , 2002, Current opinion in microbiology.

[54]  D. Livermore.  Can better prescribing turn the tide of resistance? , 2004, Nature Reviews Microbiology.

[55]  S. Sullivan,et al.  Economic Issues and Antibiotic Resistance in the Community , 2002, The Annals of pharmacotherapy.

[56]  H. Haak.  Determinants of Antimicrobial Use in the Developing World , 2002 .

[57]  Vincent A. Fischetti,et al.  Rapid Killing of Streptococcus pneumoniae with a Bacteriophage Cell Wall Hydrolase , 2001, Science.

[58]  B. Levin,et al.  The population dynamics of antimicrobial chemotherapy , 1997, Antimicrobial agents and chemotherapy.

[59]  J. Hurley.  Risk of death from methicillin‐resistant Staphylococcus aureus bacteraemia: a meta‐analysis , 2002, The Medical journal of Australia.

[60]  A. Fattom,et al.  Development of StaphVAX, a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to phase III clinical trials. , 2004, Vaccine.

[61]  R. Anderson,et al.  The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[62]  T. Nakamoto,et al.  Evaluation of panipenem/betamipron (PAPM/BP) in pneumonia in elderly patients , 2002, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[63]  F. Vandenesch,et al.  Community-Acquired Methicillin-Resistant Staphylococcus aureus Carrying Panton-Valentine Leukocidin Genes: Worldwide Emergence , 2003, Emerging infectious diseases.

[64]  P. François,et al.  Rapid Detection of Methicillin-Resistant Staphylococcus aureus Directly from Sterile or Nonsterile Clinical Samples by a New Molecular Assay , 2003, Journal of Clinical Microbiology.

[65]  A. Bruce,et al.  Urogenital infections in women: can probiotics help? , 2003, Postgraduate medical journal.

[66]  D. Livermore.  Bacterial resistance: origins, epidemiology, and impact. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[67]  Xiaoan Ruan,et al.  Novel Antibacterial Class , 2003, Antimicrobial Agents and Chemotherapy.

[68]  B. Levin,et al.  Minimizing potential resistance: a population dynamics view. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[69]  J. Coast,et al.  Antimicrobial resistance: a global response. , 2002, Bulletin of the World Health Organization.

[70]  Merrill Goozner,et al.  The $800 Million Pill: The Truth behind the Cost of New Drugs , 2004 .

[71]  R. Giroux,et al.  New Real-Time PCR Assay for Rapid Detection of Methicillin- Resistant Staphylococcus aureus Directly from Specimens Containing a Mixture of Staphylococci , 2004, Journal of Clinical Microbiology.

[72]  Mary Jane Ferraro,et al.  Linezolid resistance in a clinical isolate of Staphylococcus aureus , 2001, The Lancet.

[73]  Marc Lipsitch,et al.  Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States , 2003, Nature Medicine.

[74]  S. Langermann,et al.  Development of a recombinant FimCH vaccine for urinary tract infections. , 2003, Advances in experimental medicine and biology.

[75]  O. Cars,et al.  Suboptimal Antibiotic Dosage as a Risk Factor for Selection of Penicillin-Resistant Streptococcus pneumoniae: In Vitro Kinetic Model , 2003, Antimicrobial Agents and Chemotherapy.

[76]  I. Phillips,et al.  Antibiotic clinical trials revisited. , 2000, The Journal of antimicrobial chemotherapy.

[77]  M. Kremer,et al.  Perspectives on stimulating industrial research and development for neglected infectious diseases. , 2001, Bulletin of the World Health Organization.

[78]  A. White.  The Pharmaceutical Company Approach to Antibiotic Policies , 2005, Antibiotic Policies.

[79]  M. P. Singh,et al.  Antibacterial leads from microbial natural products discovery. , 2000, Current opinion in drug discovery & development.

[80]  J. Powers,et al.  Appropriate antimicrobial prescribing: approaches that limit antibiotic resistance. , 2001, American family physician.

[81]  S. Cosgrove,et al.  Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[82]  J. Kragstrup,et al.  [Antibiotic treatment of infections in general practice. Effect of audit assessed by prescriptions data from health insurance registry and physicians' own registration]. , 2001, Ugeskrift for laeger.

[83]  M. Hufnagel,et al.  Enterococcal infections: host response, therapeutic, and prophylactic possibilities. , 2004, Vaccine.

[84]  Robin Patel,et al.  Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. , 2002, The New England journal of medicine.

[85]  Laura Nelson,et al.  Defence work sheds light on hospital bacteria , 2004, Nature.

[86]  How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development. , 2001, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[87]  Stephan Harbarth,et al.  Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. , 2003, The American journal of medicine.

[88]  M. Woolhouse,et al.  What is antibiotic resistance and how can we measure it? , 2000, Trends in microbiology.